OrthoPediatrics (2X7) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2X7 Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

OrthoPediatrics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2X7 Stock 12 Month Forecast

Average Price Target

€24.26

▲(21.91% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for OrthoPediatrics in the last 3 months. The average price target is €24.26 with a high forecast of €30.88 and a low forecast of €19.41. The average price target represents a 21.91% change from the last price of €19.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"€11","16":"€16","21":"€21","26":"€26","31":"€31"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.87699475,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.260495874999997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.4083967,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€19.41</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,16,21,26,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19,19.913614980769232,20.82722996153846,21.740844942307692,22.654459923076924,23.568074903846153,24.481689884615385,25.395304865384617,26.30891984615385,27.222534826923077,28.13614980769231,29.049764788461538,29.96337976923077,{"y":30.87699475,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19,19.404653528846154,19.80930705769231,20.213960586538462,20.618614115384613,21.023267644230767,21.42792117307692,21.832574701923075,22.23722823076923,22.641881759615384,23.046535288461534,23.45118881730769,23.855842346153842,{"y":24.260495874999997,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19,19.03141513076923,19.062830261538462,19.09424539230769,19.125660523076924,19.157075653846153,19.188490784615386,19.219905915384615,19.251321046153848,19.282736176923077,19.31415130769231,19.34556643846154,19.37698156923077,{"y":19.4083967,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.8,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€30.88

Average Price Target€24.26

Lowest Price Target€19.41

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ryan Zimmerman

BTIG

€25.58

Buy

28.56%

Upside

Reiterated

09/15/26

OrthoPediatrics Earns Buy Rating as Innovation ‘Super Cycle’ Drives Long-Term Growth Potential; $29 Price Target Reaffirmed

Caitlin Roberts

Canaccord Genuity

€24.7

Buy

24.13%

Upside

Reiterated

08/12/26

Analysts' Top Healthcare Picks: OrthoPediatrics (KIDS), Perrigo Company (PRGO)

Michael Matson

Needham

€30.88

Buy

55.16%

Upside

Reiterated

08/05/26

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Vera Therapeutics (VERA)

Rick Wise

Stifel Nicolaus

€19.41→€21.17

Buy

6.40%

Upside

Reiterated

08/05/26

OrthoPediatrics price target raised to $24 from $22 at StifelOrthoPediatrics price target raised to $24 from $22 at Stifel

Ben Haynor

Lake Street

€29.99

Buy

50.73%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Personalis (NASDAQ: PSNL), OrthoPediatrics (NASDAQ: KIDS) and Sight Sciences (NASDAQ: SGHT)

Ravi Misra

Truist Financial

€17.64→€19.41

Hold

-2.47%

Downside

Reiterated

08/05/26

Truist Financial Sticks to Their Hold Rating for OrthoPediatrics (KIDS)

Matthew O'Brien

Piper Sandler

€19.41→€22.05

Buy

10.83%

Upside

Reiterated

08/05/26

OrthoPediatrics price target raised to $25 from $22 at Piper SandlerOrthoPediatrics price target raised to $25 from $22 at Piper Sandler

Mathew Blackman

TD Cowen

€20.29

Buy

1.96%

Upside

Reiterated

08/04/26

OrthoPediatrics Earns Buy Rating on Strong Outperformance, Expanding Margins and Multi-Year Growth Drivers

David Turkaly

Citizens JMP

€30.88→€22.05

Buy

10.83%

Upside

Reiterated

10/10/25

OrthoPediatrics price target lowered to $25 from $35 at Citizens JMPOrthoPediatrics price target lowered to $25 from $35 at Citizens JMP

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ryan Zimmerman

BTIG

€25.58

Buy

28.56%

Upside

Reiterated

09/15/26

OrthoPediatrics Earns Buy Rating as Innovation ‘Super Cycle’ Drives Long-Term Growth Potential; $29 Price Target Reaffirmed

Caitlin Roberts

Canaccord Genuity

€24.7

Buy

24.13%

Upside

Reiterated

08/12/26

Analysts' Top Healthcare Picks: OrthoPediatrics (KIDS), Perrigo Company (PRGO)

Michael Matson

Needham

€30.88

Buy

55.16%

Upside

Reiterated

08/05/26

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Vera Therapeutics (VERA)

Rick Wise

Stifel Nicolaus

€19.41→€21.17

Buy

6.40%

Upside

Reiterated

08/05/26

OrthoPediatrics price target raised to $24 from $22 at StifelOrthoPediatrics price target raised to $24 from $22 at Stifel

Ben Haynor

Lake Street

€29.99

Buy

50.73%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Personalis (NASDAQ: PSNL), OrthoPediatrics (NASDAQ: KIDS) and Sight Sciences (NASDAQ: SGHT)

Ravi Misra

Truist Financial

€17.64→€19.41

Hold

-2.47%

Downside

Reiterated

08/05/26

Truist Financial Sticks to Their Hold Rating for OrthoPediatrics (KIDS)

Matthew O'Brien

Piper Sandler

€19.41→€22.05

Buy

10.83%

Upside

Reiterated

08/05/26

OrthoPediatrics price target raised to $25 from $22 at Piper SandlerOrthoPediatrics price target raised to $25 from $22 at Piper Sandler

Mathew Blackman

TD Cowen

€20.29

Buy

1.96%

Upside

Reiterated

08/04/26

OrthoPediatrics Earns Buy Rating on Strong Outperformance, Expanding Margins and Multi-Year Growth Drivers

David Turkaly

Citizens JMP

€30.88→€22.05

Buy

10.83%

Upside

Reiterated

10/10/25

OrthoPediatrics price target lowered to $25 from $35 at Citizens JMPOrthoPediatrics price target lowered to $25 from $35 at Citizens JMP

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

OMCLOmnicell

KNSAKiniksa Pharmaceuticals

ACHVAchieve Life Sciences

AHCOAdaptHealth

ZVRAZevra Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering OrthoPediatrics

3 Months

Matthew O'BrienPiper Sandler

Success Rate

9/17 ratings generated profit

Average Return

+0.31%

Copying Matthew O'Brien's trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +0.31% per trade.

1 Year

Rick WiseStifel Nicolaus

Success Rate

9/25 ratings generated profit

Average Return

-8.42%

Copying Rick Wise's trades and holding each position for 1 Year would result in 36.00% of your transactions generating a profit, with an average return of -8.42% per trade.

2 Years

Ryan ZimmermanBTIG

Success Rate

9/28 ratings generated profit

Average Return

-13.95%

Copying Ryan Zimmerman's trades and holding each position for 2 Years would result in 32.14% of your transactions generating a profit, with an average return of -13.95% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2X7 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2X7 has received 10 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 2X7 average Analyst price target in the past 3 months is 24.26.

Each month's total comprises the sum of three months' worth of ratings.

2X7 Financial Forecast

2X7 Earnings Forecast

Next quarter’s earnings estimate for 2X7 is -€0.20 with a range of -€0.29 to -€0.13. The previous quarter’s EPS was -€0.26. 2X7 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2X7 has Performed in-line its overall industry.

2X7 Sales Forecast

Next quarter’s sales forecast for 2X7 is €60.46M with a range of €60.12M to €60.75M. The previous quarter’s sales results were €62.24M. 2X7 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2X7 has Performed in-line its overall industry.

2X7 Stock Forecast FAQ

What is DE:2X7’s average 12-month price target, according to analysts?

Based on analyst ratings, OrthoPediatrics Corp’s 12-month average price target is 24.26.

What is DE:2X7’s upside potential, based on the analysts’ average price target?

OrthoPediatrics Corp has 21.91% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is OrthoPediatrics Corp a Buy, Sell or Hold?

OrthoPediatrics Corp has a consensus rating of Strong Buy, which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is OrthoPediatrics Corp’s share price target?

The average share price target for OrthoPediatrics Corp is 24.26. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €30.88 ,and the lowest forecast is €19.41. The average share price target represents 21.91% Increase from the current price of €19.9.

What do analysts say about OrthoPediatrics Corp?

OrthoPediatrics Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of OrthoPediatrics Corp?

To buy shares of DE:2X7, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

OrthoPediatrics (2X7) Stock Forecast & Price Target

2X7 Analyst Ratings

2X7 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering OrthoPediatrics

2X7 Analyst Recommendation Trends

2X7 Financial Forecast

2X7 Earnings Forecast

2X7 Sales Forecast

2X7 Stock Forecast FAQ

Detailed List of Analyst Forecasts